A cancer-derived mutation in the PSTAIRE helix of cyclin-dependent kinase 2 alters the stability of cyclin binding

Biochim Biophys Acta. 2010 Jul;1803(7):858-64. doi: 10.1016/j.bbamcr.2010.04.004. Epub 2010 Apr 24.

Abstract

Cyclin-dependent kinase 2 (cdk2) is a central regulator of the mammalian cell cycle. Here we describe the properties of a mutant form of cdk2 identified during large-scale sequencing of protein kinases from cancerous tissue. The mutation substituted a leucine for a proline in the PSTAIRE helix, the central motif in the interaction of the cdk with its regulatory cyclin subunit. We demonstrate that whilst the mutant cdk2 is considerably impaired in stable cyclin association, it is still able to generate an active kinase that can functionally complement defective cdks in vivo. Molecular dynamic simulations and biophysical measurements indicate that the observed biochemical properties likely stem from increased flexibility within the cyclin-binding helix.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cell Line
  • Circular Dichroism
  • Cyclin E / genetics
  • Cyclin E / metabolism*
  • Cyclin-Dependent Kinase 2 / chemistry*
  • Cyclin-Dependent Kinase 2 / genetics
  • Cyclin-Dependent Kinase 2 / metabolism*
  • Humans
  • Models, Molecular
  • Molecular Dynamics Simulation
  • Molecular Sequence Data
  • Mutation*
  • Neoplasms / genetics*
  • Oncogene Proteins / genetics
  • Oncogene Proteins / metabolism*
  • Protein Binding
  • Protein Structure, Tertiary

Substances

  • CCNE1 protein, human
  • Cyclin E
  • Oncogene Proteins
  • CDK2 protein, human
  • Cyclin-Dependent Kinase 2